DeepMed Research

ONCOC4, INC.

🇦🇺Australia

Country: 🇦🇺Australia

Ownership: Private

Established: 2020-01-01

Employees: 11

Market Cap: -

Website: http://oncoc4.com

Clinical Trials

Safety, Pharmacokinetics, and Efficacy of AI-081, a Bispecific Antibody for PD-1 And VEGF in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: AI-081

First Posted Date: 2024-10-10

Last Posted Date: 2025-05-20

Lead Sponsor: OncoC4, Inc.

Target Recruit Count: 204

Registration Number: NCT06635785

Locations: 🇺🇸
University of Alabama at Birmingham, Birmingham, Alabama, United States
🇺🇸
Highlands Oncology Group, Springdale, Arkansas, United States
🇺🇸
University of Florida UF Health Cancer Center, Gainesville, Florida, United States

and more 14 locations

Safety, Pharmacokinetics (PK), and Efficacy of ONC 841 in Advanced Solid Tumors

Phase 1

Recruiting

Conditions: Advanced Solid Tumor

Interventions: Drug: ONC-841

First Posted Date: 2024-04-08

Last Posted Date: 2025-03-05

Lead Sponsor: OncoC4, Inc.

Target Recruit Count: 30

Registration Number: NCT06352359

Locations: 🇺🇸
University of California at Davis Cancer Center, Sacramento, California, United States
🇺🇸
UF Health Cancer Center, University of Florida, Gainesville, Florida, United States
🇺🇸
AdventHealth Medical Group Oncology Research at Celebration, Kissimmee, Florida, United States

and more 5 locations

Safety, Tolerability, Immunogenicity and Pharmacokinetics of ONC-841

Phase 1

Withdrawn

Conditions: Advanced Solid Tumor

Interventions: Other: Placebo
Drug: ONC-841

First Posted Date: 2024-01-23

Last Posted Date: 2024-04-03

Lead Sponsor: OncoC4, Inc.

Registration Number: NCT06219499

Safety, PK and Efficacy of AI-061 in Advanced Solid Tumors

Phase 1

Active, not recruiting

Conditions: Melanoma
Non Small Cell Lung Cancer
Head and Neck Squamous Cell Carcinoma
High Grade Serous Adenocarcinoma of Ovary
Primary Peritoneal Carcinoma
Fallopian Tube Cancer
Endometrial Cancer
Cervical Cancer
Renal Cell Carcinoma
Bladder Cancer

Interventions: Drug: AI-061

First Posted Date: 2023-05-15

Last Posted Date: 2025-02-03

Lead Sponsor: OncoC4, Inc.

Target Recruit Count: 18

Registration Number: NCT05858736

Locations: 🇦🇺
St. Vincent's Private Hospital, Darlinghurst, New South Wales, Australia
🇦🇺
Mater Misericordiae Ltd., Brisbane, Queensland, Australia
🇦🇺
Tasman Oncology Research, Southport, Queensland, Australia

and more 2 locations

ONC-392 Plus Lutetium Lu 177 Vipivotide Tetraxetan in Patients With mCRPC

Phase 1

Recruiting

Conditions: Metastatic Castration-resistant Prostate Cancer

Interventions: Drug: ONC-392 low
Drug: ONC-392 high
Drug: lutetium Lu 177 vipivotide tetraxetan

First Posted Date: 2023-01-12

Last Posted Date: 2025-04-08

Lead Sponsor: OncoC4, Inc.

Target Recruit Count: 141

Registration Number: NCT05682443

Locations: 🇺🇸
UC Davis Comprehensive Cancer Center, Sacramento, California, United States
🇺🇸
Rocky Mountain Cancer Centers USOR, Aurora, Colorado, United States
🇺🇸
Moffitt Cancer Cancer, Tampa, Florida, United States

and more 20 locations

ONC-392 Versus Docetaxel in Metastatic NSCLC That Progressed on PD-1/PD-L1 Inhibitors

Phase 3

Recruiting

Conditions: Non Small Cell Lung Cancer

Interventions: Drug: Gotistobart
Drug: Docetaxel

First Posted Date: 2023-01-04

Last Posted Date: 2025-02-24

Lead Sponsor: OncoC4, Inc.

Target Recruit Count: 600

Registration Number: NCT05671510

Locations: 🇦🇺
Bankstown Hospital - 3305, Bankstown, New South Wales, Australia
🇦🇺
Newcastle Private Hospital - 3302, New Lambton Heights, New South Wales, Australia
🇦🇺
Mater - 3301, Newstead, Queensland, Australia

and more 160 locations

ONC-392 and Pembrolizumab in Platinum Resistant Ovarian Cancer

Phase 2

Active, not recruiting

Conditions: Ovarian Cancer
High Grade Serous Adenocarcinoma of Ovary
Primary Peritoneal Carcinoma
Fallopian Tube Cancer

Interventions: Drug: ONC-392
Drug: Pembrolizumab

First Posted Date: 2022-07-06

Last Posted Date: 2025-02-03

Lead Sponsor: OncoC4, Inc.

Target Recruit Count: 58

Registration Number: NCT05446298

Locations: 🇺🇸
Cancer Treatment Centers of America, Phoenix. 403, Goodyear, Arizona, United States
🇺🇸
Honor Health, USOR, 406, Phoenix, Arizona, United States
🇺🇸
Nuvance Health System, 401, Danbury, Connecticut, United States

and more 18 locations

Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC

Phase 1

Recruiting

Conditions: Metastatic Head and Neck Carcinoma
Metastatic Colorectal Cancer
Metastatic Prostate Cancer
Gastric Cancer
Non Small Cell Lung Cancer
Metastatic Melanoma
Ovarian Cancer
Salivary Gland Cancer
Urothelial Carcinoma
Advanced Solid Tumor

Interventions: Drug: ONC-392
Drug: Docetaxel
Drug: Pembrolizumab

First Posted Date: 2019-10-28

Last Posted Date: 2025-02-03

Lead Sponsor: OncoC4, Inc.

Target Recruit Count: 733

Registration Number: NCT04140526

Locations: 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸
The Oncology Institute of Hope and Innovation, Downey, California, United States
🇺🇸
University of California at Davis, Davis, California, United States

and more 34 locations

Prev
1
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy